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orBACKGROUND Heart failure (HF) trials initiated in the last century highlighted many differences between men and
women. Of particular concern was undertreatment of women compared with men, but much has changed during the past
20 years.
OBJECTIVES This study sought to identify these changes, which may give a new perspective on the management of,
and outcomes in, women with HF.
METHODS The study analyzed 12,058 men and 3,357 women enrolled in 2 large HF with reduced ejection fraction
(HFrEF) trials with near identical inclusion and exclusion criteria and the same principal outcomes. Outcomes were
adjusted for other prognostic variables including N-terminal pro–B-type natriuretic peptide.
RESULTS Women were older and more often obese than men were, had slightly higher systolic blood pressure and
heart rate, and were less likely to have most comorbidities, except hypertension. Women had more symptoms and signs
(e.g., pedal edema 23.4% vs 19.9%; p < 0.0001) and worse quality of life—median Kansas City Cardiomyopathy
Questionnaire Clinical Summary Score 71.3 (interquartile range: 53.4 to 86.5) versus 81.3 (interquartile range: 65.1 to
92.7; p < 0.0001)—despite similar left ventricular ejection fraction and N-terminal pro–B-type natriuretic peptide.
However, women had lower mortality (adjusted hazard ratio: 0.68; 95% confidence interval: 0.62 to 0.74; p < 0.001)
and risk of HF hospitalization (hazard ratio: 0.80; 95% confidence interval: 0.72 to 0.89; p < 0.001). Diuretics and
anticoagulants were underutilized in women. Device therapy was underused in both men and women, but more so in
women (e.g., defibrillator 8.6% vs. 16.6%; p < 0.0001).
CONCLUSIONS Although women with HFrEF live longer than men, their additional years of life are of poorer quality,
with greater self-reported psychological and physical disability. The explanation for this different sex-related
experience of HFrEF is unknown as is whether physicians recognize it. Women continue to receive suboptimal
treatment, compared with men, with no obvious explanation for this shortfall. (J Am Coll Cardiol 2019;73:29–40)
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30A series of trials initiated in the lastcentury highlighted many differ-ences between men and women
with heart failure (HF) (1–8). Of particular
concern in these trials and other studies
was the suggestion that, in common with
other cardiovascular (CV) conditions, women
were less well treated than men were (1–13).
Since those trials were initiated, much has
changed in the assessment and management
of patients with HF. Natriuretic peptides are
now measured routinely (14,15). Beta-
blockers are recommended for all patients
with HF with reduced ejection fraction
(HFrEF), whereas in the largest previous
comparison of men and women were used
in only 55% of patients (7). Similarly, the
indication for mineralocorticoid receptor an-
tagonists (MRAs) has broadened to patients
with mild symptoms, as has the indication
for cardiac resynchronization therapy (the
effectiveness of which had not even been
demonstrated when many of the previous
studies were conducted) (14,15). All of these
changes may give a new perspective on the
management of, and outcomes in, women
with HFrEF.
Herein, we compared women and men
with HF enrolled in the 2 most recent and
largest randomized controlled trials of phar-macological therapy in patients with HFrEF (16,17).SEE PAGE 41METHODS
TRIALS AND PARTICIPANTS. The inclusion and
exclusion criteria of the PARADIGM-HF (Prospective
comparison of ARNI [Angiotensin Receptor Neprilysin
Inhibitor] with ACEI to Determine Impact on Global
Mortality and morbidity in Heart Failure) and AT-
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tical (16,17). Briefly, patients were eligible at
screening if $18 years of age, New York Heart Asso-
ciation (NYHA) functional class II to IV, left ventric-
ular ejection fraction (LVEF) #35% (changed
from #40% in the PARADIGM-HF trial by amend-
ment), elevated natriuretic peptide level, taking an
angiotensin-converting enzyme (ACE) inhibitor or
angiotensin receptor blocker (ARB), beta-blocker
(unless contraindicated or not tolerated), and MRA,
if indicated. The natriuretic peptide eligibility criteria
were plasma B-type natriuretic peptide $150 pg/ml or
N-terminal pro–B-type natriuretic peptide (NT-
proBNP) $600 pg/ml; patients hospitalized in the
preceding 12 months were eligible with a lower level:
B-type natriuretic peptide $100 pg/ml or NT-
proBNP $400 pg/ml.
Exclusion criteria included symptomatic hypoten-
sion or systolic blood pressure (SBP) <95 mm Hg
(<90 mm Hg in the ATMOSPHERE trial), estimated
glomerular filtration rate (eGFR) <30 ml/min/1.73 m2
(<35 ml/min/1.73 m2 in the ATMOSPHERE trial), and
potassium >5.4 mmol/l (>5.2 mmol/l in the ATMO-
SPHERE trial). The trial was approved by ethics
committees at 1,043 participating centers in 47
countries in the PARADIGM-HF trial and 789 centers
in 43 countries in the ATMOSPHERE trial, and all
patients provided written informed consent.
On trial entry, ACE inhibitor or ARB therapy was
stopped and patients entered a sequential run-in,
first receiving enalapril followed by sacubitril/val-
sartan in the PARADIGM-HF trial and enalapril fol-
lowed by the combination of enalapril plus aliskiren
in the ATMOSPHERE trial. Patients tolerating both
run-in periods were randomly assigned to double-
blind therapy with sacubitril/valsartan or enalapril
in a 1:1 ratio in the PARADIGM-HF trial or enalapril,
aliskiren, or both drugs in a 1:1:1 ratio in the
ATMOSPHERE trial.
The median duration of follow-up was 26.6 months
in the PARADIGM-HF trial (minimum 1 day,i has served as a consultant for Novartis, Abbott,
fic, and Boehringer Ingelheim. Dr. Packer has served
rdiorentis, Daiichi-Sankyo, Gilead, Relypsa, Sanofi,
Novartis and AstraZeneca. Dr. Solomon has received
ers Squibb, Celladon, Gilead, GlaxoSmithKline, Ionis,
al Heart, Lung, and Blood Institute, Novartis, Sanofi
, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb,
, Takeda, Theracos, Quantum Genetics, Cardurion,
eneca, Novartis, and Servier. All other authors have
er to disclose.
er 21, 2018, accepted September 25, 2018.
TABLE 1 Baseline Characteristics of Men and Women With HFrEF
Women
(n ¼ 3,357)
Men
(n ¼ 12,058) p Value
Age, yrs 65.10  11.9 63.10  11.5 <0.0001
Age group <0.001
#40 yrs 104 (3.1) 464 (3.8)
41–55 yrs 584 (17.4) 2,374 (19.7)
56–70 yrs 1,436 (42.8) 5,832 (48.4)
>70 yrs 1,233 (36.7) 3,388 (28.1)
Region <0.001
North America 132 (3.9) 647 (5.4)
Latin America 698 (20.8) 1,854 (15.4)
Western Europe and
other
733 (21.8) 3,221 (26.7)
Central Europe 1,113 (33.2) 3,657 (30.3)
Asia-Pacific 681 (20.3) 2,679 (22.2)
Race <0.001
Caucasian 2,128 (63.4) 8,008 (66.4)
Black 166 (4.9) 371 (3.1)
Asian 664 (19.8) 2,609 (21.6)
Others 399 (11.9) 1,070 (8.9)
SBP, mm Hg 123.9  17.0 122.0  16.7 <0.0001
Heart rate, beats/min 72.8  11.7 71.9  12.4 <0.0001
BMI, kg/m2 27.1 (24–32) 27.1 (24–31) 0.136
Weight category* <0.001
Underweight 118 (3.5) 189 (1.6)
Normal 1,005 (30.0) 3,560 (29.6)
Overweight 1,106 (33.0) 4,764 (39.6)
Obese 1,120 (33.4) 3,524 (29.2)
Continued in the next column
TABLE 1 Continued
Women
(n ¼ 3,357)
Men
(n ¼ 12,058) p Value
Comorbidities
Atrial fibrillation
(history)
1,093 (32.6) 4,388 (36.4) <0.0001
Hypertension 2,369 (70.6) 7,903 (65.5) <0.0001
Coronary artery
disease
1,444 (43.0) 6,755 (56.0) <0.0001
Myocardial infarction 1,007 (30.0) 5,474 (45.4) <0.0001
Unstable angina 307 (9.1) 1,414 (11.7) <0.0001
Stable angina 698 (20.8) 2,409 (20.0) 0.299
Prior PCI 445 (13.3) 2,735 (22.7) <0.0001
Ischemic etiology 24.2 35.2
Nonischemic 2.3 3.5
Prior CABG 226 (6.7) 2,055 (17.0) <0.0001
Ischemic etiology 12.9 27.6
Nonischemic 0.7 1.0
Clinically significant
valve disease
178 (5.3) 553 (4.6) 0.084
Cerebrovascular
disease
362 (10.8) 1,574 (13.1) 0.004
Stroke 248 (7.4) 969 (8.0) 0.218
Known carotid artery
disease
69 (2.1) 443 (3.7) <0.0001
Peripheral arterial
disease
93 (2.0) 719 (6.0) <0.0001
Prior lower limb
revascularization
28 (0.8) 233 (1.9) <0.0001
Intermittent
claudication
78 (2.3) 596 (4.9) <0.0001
Asthma 173 (5.2) 354 (2.9) <0.0001
COPD 285 (8.5) 1,582 (13.1) <0.0001
Diabetes 1,041 (31.0) 3,810 (31.6) 0.517
Renal disease 392 (11.7) 1,671 (13.9) 0.001
Cancer 153 (4.6) 505 (4.2) 0.349
Anemia† 700 (20.9) 2,610 (21.7) 0.3221
Lifestyle habits
Smoking status <0.001
Never smoked 2,694 (80.3) 5,427 (45.0)
Ex-smoker 456 (13.6) 4,729 (39.2)
Current smoker 207 (6.2) 1,902 (15.8)
Alcohol, U/day <0.001
<1 3,269 (97.4) 10,273 (85.2)
1–2 79 (2.4) 1,442 (12.0)
>2 8 (0.2) 342 (2.8)
Values are mean  SD, n (%), median (interquartile range), or %. *29 were
missing. †Hemoglobin <130 g/l (men), <120 g/l (women)
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting;
COPD ¼ chronic obstructive pulmonary disease; HFrEF ¼ heart failure with
reduced ejection fraction; PCI ¼ percutaneous coronary intervention;
SBP ¼ systolic blood pressure.
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31maximum 4.2 years) and 36.7 months (minimum
1 day, maximum 6.2 years) in the ATMOSPHERE trial.
OUTCOMES. The primary outcome for both trials was
the composite of first HF hospitalization or CV death.
In this study, we analyzed the primary outcome, its
components, sudden death, pump failure death, non-
CV death, and all-cause death in women compared
with men. We have also reported recurrent hospital-
izations for HF, all CV, non-CV, and all causes. All
events except non-HF, non–myocardial infarction
(MI), and nonstroke CV hospitalizations, and non-CV
hospitalizations were adjudicated by the same clin-
ical endpoint committee using prespecified criteria.
In both trials, health-related quality of life (HRQL)
was measured at baseline in 13,061 patients using the
Kansas City Cardiomyopathy Questionnaire (KCCQ)
score, which is scored from 0 to 100, with lower
scores indicating a poorer HRQL (18). General quality
of life was measured using the EQ-5D-3L in the
PARADIGM-HF trial.
STATISTICAL ANALYSIS. Baseline characteristics of
patients are reported as mean  SD, proportions, or
median (interquartile range). Statistical tests
employed were 2-sample Student’s t test, chi-square
test, and Mann-Whitney U test, respectively.Competing-risks regression, using the Fine-Gray
method, was used to assess the outcomes. The
primary outcome and CV death were analyzed ac-
counting for the competing risk of non-CV death.
First, HF hospitalization was analyzed accounting
for the competing risk of all-cause death. Sudden
deaths were analyzed accounting for the competing
TABLE 2 Heart Failure: Clinical Characteristics, Investigations, and Treatment in Men and
Women With HFrEF
Women
(n ¼ 3,357)
Men
(n ¼ 12,058) p Value
HF etiology <0.001
Ischemic 1,677 (50.0) 7,289 (60.5)
Nonischemic 1,494 (44.5) 4,277 (35.5)
Other 186 (5.5) 492 (4.1)
Time since HF diagnosis <0.001
<1 yr 1,168 (34.8) 3,716 (30.8)
1–5 yrs 1,267 (37.7) 4,558 (37.8)
>5 yrs 922 (27.5) 3,780 (31.4)
NYHA functional class* <0.001
I 92 (2.7) 470 (3.9)
II 2,182 (65.0) 8,577 (71.2)
III 1,046 (31.2) 2,915 (24.2)
IV 37 (1.1) 83 (0.7)
Prior hospitalization for HF 1,951 (58.1) 7,511 (62.3) <0.0001
LVEF, % 29.6  5.9 28.8  6.0 <0.0001
KCCQ clinical summary score 71.3 (53.4–86.5) 81.3 (65.1–92.7) 0.001
Symptoms/signs
Dyspnea at rest 204 (6.1) 408 (3.4) <0.0001
Dyspnea on effort 2,976 (88.7) 10,191 (84.7) <0.0001
Orthopnea 290 (8.6) 681 (5.7) <0.0001
PND 237 (7.1) 519 (4.3) <0.0001
Edema 787 (23.4) 2,403 (19.9) <0.0001
Rales <0.001
Basilar only 350 (10.4) 947 (7.9)
Greater than one-third of lung field 9 (0.3) 59 (0.5)
Third heart sound 341 (10.2) 1,048 (8.7) 0.009
JVD 365 (10.9) 1,112 (9.2) 0.004
ECG findings
Atrial fibrillation 732 (21.8) 2,905 (24.1) 0.006
LBBB 750 (22.3) 2,332 (19.3) 0.0001
RBBB 182 (5.4) 956 (7.9) <0.0001
QRS duration, ms 104 (86–140) 110 (94–140) <0.0001
Laboratory investigations
NT-proBNP, pg/ml 1,448 (801–2,805) 1,406 (761–2,770) 0.158
Hemoglobin, g/l 129.9  14.4 141.0  15.7 <0.0001
Creatinine, mmol/l 81.0  21.6 100.0  25.5 <0.0001
eGFR, ml/min/1.73 m2 68.2  25.0 71.2  21.3 <0.0001
eGFR <60 ml/min/1.73 m2 1,267 (37.7) 3,643 (30.2) <0.001
Baseline treatments and
prior interventions
Diuretic 2,698 (80.4) 9,638 (79.9) 0.574
Loop diuretics†‡ 2,523 (75.2) 9,135 (75.8) 0.4721
Thiazides†‡ 265 (7.9) 789 (6.5) 0.0061
Continued on the next page
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32risk of all nonsudden death and pump failure
deaths were analyzed accounting for the competing
risk of deaths not caused by pump failure. Non-CV
deaths were analyzed accounting for the
competing risk of all CV death. Fatal and nonfatal
MI and strokes were analyzed accounting for the
competing risk of all-cause death not due to MI or
stroke. Along with the crude hazard ratios (HRs), we
report adjusted HRs from models including age,heart rate, SBP, NT-proBNP, body mass index,
NYHA functional class, LVEF, and eGFR. HF hospi-
talization was additionally adjusted for previous HF
hospitalization. All models were adjusted for ran-
domized treatment and region.
Recurrent hospitalizations (for HF, CV, non-CV,
and all causes) were analyzed using a negative bino-
mial regression model. Both crude incidence rate ra-
tios (IRRs) and IRRs adjusted for the variables
mentioned previously are reported. All analyses were
conducted using STATA version 14 (StataCorp, Col-
lege Station, Texas).
RESULTS
There were 12,058 men and 3,357 women in our
analysis, accounting for 78.2% and 21.8% of the
cohort, respectively.
BASELINE CHARACTERISTICS. The baseline charac-
teristics in men and women are shown in Table 1.
Women were on average 2 years older than men, had
higher SBP, and had a higher heart rate. There was no
significant difference in body mass index, but women
were more often obese (33.4% women vs. 29.2%
men).
PRE-EXISTING COMORBIDITIES. Apart from hyper-
tension (70.6% women vs. 65.5% men) and clinically
significant valvular disease (5.3% vs. 4.6%), women
were less likely to have a history of major comorbid
conditions such as atrial fibrillation (AF) (32.6% vs.
36.4%), previous MI (30.0% vs. 45.4%), and stroke
(7.4% vs 8.0%). As well as having a lower prevalence
of coronary artery disease (CAD), women had a much
lower rate of prior coronary revascularization.
Among non-CV comorbidities, women had a
similar prevalence of diabetes (31.0% vs. 31.6%) but a
lower prevalence of chronic obstructive pulmonary
disease (8.5% vs. 13.1%). Women were also less likely
to be current smokers (6.2% vs. 15.8%) and had lower
intake of alcohol.
In the EQ-5D-3L state of health score, women were
much more likely to report moderate to extreme
anxiety or depression (44.0% in women vs. 29.0% in
men; p < 0.0001) (PARADIGM-HF trial only). This was
especially true of women with an ischemic etiology
(Online Tables 1 and 2).
HF CHARACTERISTICS AND INVESTIGATIONS AT
BASELINE. As shown in Table 2, fewer women had
been living with a diagnosis of HF for >5 years (27.5%
vs. 31.4%) and had been hospitalized for HF less often
than men (58.1% vs. 62.3%). They were also less likely
to have an ischemic etiology (50.0% vs. 60.5%).
TABLE 2 Continued
Women
(n ¼ 3,357)
Men
(n ¼ 12,058) p Value
Digitalis 1,089 (32.4) 3,692 (30.6) 0.048
Beta-blocker 3,075 (91.6) 11,168 (92.6) 0.049
MRA 1,555 (46.3) 5,718 (47.4) 0.2599
ACE inhibitor 2,842 (84.7) 10,697 (88.7) <0.0001
ARB 551 (16.4) 1,434 (11.9) <0.0001
CCB§ 330 (9.8) 1,035 (8.6) 0.0245
Statins 1,598 (47.6) 6,787 (56.3) <0.0001
Aspirin 1,557 (46.4) 6,393 (53.0) <0.0001
Anticoagulants 897 (26.7) 3,906 (32.4) <0.0001
In patients with atrial fibrillation on ECG 67.1 71.2 0.029
In patients with atrial fibrillation history 60.6 66.6 <0.001
CHA2DS2-VASc score $2 67.1 71.5 0.019
Pacemaker 310 (9.2) 1,490 (12.4) <0.0001
ICD (including CRT-D) 290 (8.6) 2,001 (16.6) <0.0001
ICD only 196 (5.8) 1,371 (11.4) <0.0001
CRT-P or CRT-D 137 (4.1) 830 (6.9) <0.0001
Values are n (%), mean  SD, median (interquartile range), or %. *13 were missing. †Proportion of total pop-
ulation. ‡Sixty-eight others or other combinations. §Dihydropyridine calcium-channel blocker (CCB).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CHA2DS2-VASc ¼ congestive
heart failure, hypertension, age $75 years, diabetes mellitus, prior stroke or transient ischemic attack or
thromboembolism, vascular disease, age 65–74 years, sex category; CRT-D ¼ cardiac resynchronization therapy
with defibrillator; CRT-P ¼ cardiac resynchronization therapy with pacemaker; ECG ¼ electrocardiogram;
eGFR ¼ estimated glomerular filtration rate; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection
fraction; ICD ¼ implantable cardioverter-defibrillator; JVD ¼ jugular venous distension; KCCQ ¼ Kansas City
Cardiomyopathy Questionnaire; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection fraction;
MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide;
NYHA ¼ New York Heart Association; PND ¼ paroxysmal nocturnal dyspnea; RBBB ¼ right bundle branch block.
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33Women had more symptoms than men, with a
higher prevalence of dyspnea on effort (88.7% vs.
84.7%), paroxysmal nocturnal dyspnea (7.1% vs.
4.3%), and more evidence of congestion (peripheral
edema, jugular venous congestion, and rales).
Women also had a slightly but significantly higher
LVEF (29.6% vs. 28.8%), but median NT-proBNP was
not significantly different (women 1,448 pg/ml vs.
men 1,406 pg/ml) and B-type natriuretic peptide
(PARADIGM-HF trial only) was lower in women than
men: 234 (interquartile range: 142 to 430) pg/ml
versus 259 (interquartile range: 157 to 478) pg/ml (p <
0.0001). Other biomarkers (measured in the PARADIGM-
HF trial only) are shown in Online Tables 3 and 4.
Mean eGFR was lower in women and a higher pro-
portion of women had an eGFR <60 ml/min/1.73 m2.
Women were more likely to be in a higher NYHA
functional class and had lower (worse) median KCCQ
scores. Most of the individual KCCQ domain scores
were also lower in women (Figure 1, Online Figure 1).
The EQ-5D-3L state of health score (PARADIGM-HF
trial only) showed large differences between women
and men in their mobility, ability to undertake usual
activities, and ability to self-care (washing and dres-
sing) (Online Table 1).
TREATMENT AT BASELINE. The rates of use of a
diuretic, beta-blocker, and MRA were very similar in
women and men (Table 2). Women were slightly more
likely to receive digitalis (32.4% vs. 30.6%) and ARBs
(16.4% vs. 11.9%) compared with men, and less likely
to receive an ACE inhibitor (84.7% vs. 88.7%). The
difference in rates of use of statins, aspirin, and an-
ticoagulants were larger (47.6% vs. 56.3%, 46.4% vs.
53.0%, and 26.7% vs. 32.4% in women and men,
respectively).
Women were less likely to have received a device
than men: implantable cardioverter-defibrillator
(8.6% vs. 16.6%) and cardiac resynchronization ther-
apy (4.1% vs. 6.9%). Women were also less likely to
have received influenza vaccination in the 12 months
before enrollment (19.2% vs. 21.6%; p ¼ 0.024), to
have been enrolled in a disease management program
(13.3% vs. 15.8%; p¼ 0.008) or to have been prescribed
an exercise regimen (15.0% vs. 18.1%; p ¼ 0.002)
(PARADIGM-HF trial only) (Online Table 5). Treatment
during follow-up is shown in Online Table 6.
OUTCOMES. Women had a significantly lower rate of
the primary composite outcome (9.88 vs. 12.52 events
per 100-person years), with an adjusted HR of 0.75
(95% confidence interval [CI]: 0.69 to 0.81), as shown
in Table 3 and Figure 2. Looking at the components of
this composite, the rate and risk of first hospitaliza-
tion for HF was also lower in women (adjusted HR:
0.80; 95% CI: 0.72 to 0.89).The risk of CV death was also lower, as were each of
the 2 major modes of CV death (i.e., sudden death and
pump failure death). The adjusted HRs for these
outcomes (0.65 to 0.70) were lower than for HF hos-
pitalization. Interestingly, the risk of non-CV death
was also lower in women and, as a result, so was the
risk of all-cause death (adjusted HR for non-CV death:
0.66; 95% CI: 0.52 to 0.83; HR for all-cause death:
0.68; 95% CI: 0.62 to 0.74).
When outcomes were examined according to
investigator-reported etiology (nonischemic vs.
ischemic), men with both nonischemic and ischemic
etiology did worse than women in the corresponding
groups did (Online Table 7, Online Figure 2). Among
men, those with an ischemic etiology had higher
mortality rates than did individuals with a non-
ischemic etiology. However, among women mortality
did not vary by etiology (i.e., the “protection”
conferred by a nonischemic background in men
[compared with an ischemic substrate] seemed to be
absent in women) (Online Figure 2).
Although women were less likely to have a fatal or
nonfatal MI than men (1.08 vs. 1.33 events per 100
person-years), the rate of stroke was higher in women
(1.54 vs. 1.19 events per 100 person-years).
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34RECURRENT EVENTS. During a median follow-up of
908 (interquartile range: 1 to 2,285) days, there was
a total of 3,006 hospitalizations for any cause in
women and 13,641 hospitalizations for any cause
in men (Table 4). Of these, 750 (25.1%) were due to HF
in women and 3,569 (26.2%) were due to HF in
men. Among women, 4.3% had >1 hospitalization
for HF and the same was true for 6.4% of men
(Online Table 8).
The adjusted IRR for recurrent HF hospitalization
for women compared with men was 0.69 (95% CI: 0.61
to 0.79). The IRRs for CV hospitalization (0.73; 95%
CI: 0.67 to 0.79), all-cause hospitalization (0.75; 95%
CI: 0.71 to 0.81), and non-CV hospitalization (0.82;
95% CI: 0.75 to 0.89) were higher than for HF
hospitalization.
DISCUSSION
In an analysis of 15,415 patients, including 3,357
women from 55 countries, we confirmed many known
differences between men and women (Central
Illustration) (2–4,7). In addition, we identified some
new differences and, importantly, showed a narrow-
ing of previously highlighted gaps, especially in
pharmacological treatment (although anticoagulants
were still underutilized in women). However, prob-
lems persist—women were undertreated with devices
and less likely to receive influenza vaccination, be
enrolled in a disease-management program, or be
prescribed an exercise regimen.
BASELINE CHARACTERISTICS. Women remain the
minority of patients with HFrEF enrolled in trials
because HFrEF is more common in men. Women are
older than men and less likely to have an ischemic
etiology. Both physician-assessed (NYHA functional
class) and patient-reported (KCCQ) severity of HF was
greater in women than men. Women had more
symptoms and signs of HF (and congestion), despite
having more recently diagnosed HF, higher mean
LVEF, and similar NT-proBNP (and even lower B-type
natriuretic peptide). Prior HF hospitalization was less
common in women than men. Looking at other
markers of severity, more women had an
eGFR <60 ml/min/1.73 m2 and their SBP was slightly
higher than in men. The most striking difference was
the large (10-point) difference in the median KCCQ
score. This is notable given that older patients,
generally report better HRQL, compared with younger
patients, and women were older than men (19). To
explore what lay behind this difference we examined
different KCCQ domains. The largest difference was
in “physical limitations.” This was supported by the
state of health score (from the EQ-5D-3L), whichshowed striking differences between women and men
in mobility, ability to undertake usual activities, and
ability to self-care. The reasons for these differences
in symptoms and HRQL between men and women are
not clear, as they do not seem to be explained by
major differences in physiological markers of HF
severity (see the previous text) or by comorbidities
(see the following text). Clearly, however, HF appears
to have a greater impact on the lives of women,
compared with men, and women live with more
symptoms and worse disease-specific and general
quality of life than men do.
The pattern of comorbidity differed strikingly be-
tween men and women. Given their less frequent
ischemic etiology, women had fewer manifestations
of CAD and atherothrombotic disease more generally.
Conversely, a history of hypertension was more
common in women. Obesity was also more common
although diabetes was not. AF was less common in
women and chronic obstructive pulmonary disease
much less common, in keeping with the lower rate of
previous or current smoking in women (although this
again highlights the greater dyspnea experienced by
women). Although the prevalence of anemia was
similar between men and women, mean hemoglobin
in women was 12 g/l, lower than in men. A remarkable
proportion of women (45%) self-reported moderate-
to-extreme anxiety or depression using the EQ-5D-3L
score (especially if their etiology was ischemic). This
may suggest HF has a greater psychological impact on
women than on men. These findings of worse symp-
toms and more physical and psychological disability
related highlight the underutilization of disease-
management programs and exercise regimens in
women, the interventions likely to be particularly
helpful for these problems.
TREATMENT AT BASELINE. Prior treatment with a
renin-angiotensin system blocker was required in the
PARADIGM-HF and ATMOSPHERE trials, and women
were more often treated with an ARB (as opposed to
an ACE inhibitor) compared with men, probably
reflecting higher likelihood of cough with ACE in-
hibitor in women (20,21). Beta-blocker use was also
required, unless not tolerated or contraindicated, and
was similar between sexes. MRA use was at the in-
vestigators’ discretion and was similar between
sexes. Although women had more congestion than
men did, use of diuretic was similar between the
sexes, as was use of digoxin, even though women had
less AF, and despite digoxin use being associated
with greater mortality in women (22). Overall there-
fore, and contrary to previous reports, we did not find
evidence of significant undertreatment of women
with most HF medications, except, perhaps diuretics
FIGURE 1 Scores for Each Individual Domain of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure With Reduced Ejection
Fraction at Baseline
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TABLE 3 Clinical Outcomes in Men and Women With HFrEF
Total Events Events per 100 Person-Years (95% CI) Women vs. Men
Women
(n ¼ 3,357)
Men
(n ¼ 12,058)
Women
(n ¼ 3,357)
Men
(n ¼ 12,058)
Unadjusted HR
(95% CI) p Value
Adjusted HR
(95% CI) p Value
Primary composite outcome 808 (24.1) 3,592 (29.8) 9.88 (9.22–10.59) 12.52 (12.12–12.94) 0.79 (0.73–0.85)
<0.001
0.75 (0.69–0.81)
<0.001
First hospitalization for HF* 460 (13.7) 2,059 (17.1) 5.63 (5.13–6.16) 7.18 (6.87–7.50) 0.81 (0.74–0.90)
<0.001
0.80 (0.72–0.89)
<0.001
CV death 508 (15.1) 2,364 (19.6) 5.74 (5.27–6.27) 7.56 (7.26–7.87) 0.74 (0.67–0.81)
<0.001
0.70 (0.63–0.77)
<0.001
Sudden death 196 (5.8) 1,022 (8.5) 2.22 (1.93–2.55) 3.27 (3.07–3.47) 0.67 (0.57–0.78)
<0.001
0.65 (0.56–0.76)
<0.001
Pump failure death 119 (3.5) 616 (5.1) 1.35 (1.12–1.61) 1.97 (1.82–2.13) 0.70 (0.57–0.85)
<0.001
0.67 (0.55–0.82)
<0.001
Non-CV death 93 (2.8) 476 (3.9) 1.05 (0.86–1.29) 1.52 (1.39–1.66) 0.71 (0.57–0.89)
0.003
0.66 (0.52–0.83)
<0.001
All-cause death 601 (17.9) 2,840 (23.6) 6.80 (6.27–7.36) 9.08 (8.75–9.42) 0.73 (0.67–0.80)
<0.001
0.68 (0.62–0.74)
<0.001
Fatal/nonfatal MI 94 (2.8) 412 (3.4) 1.08 (0.88–1.32) 1.33 (1.21–1.47) 0.86 (0.69–1.08)
0.186
0.79 (0.63–1.00)
0.048
Fatal/nonfatal stroke 134 (4.0) 368 (3.1) 1.54 (1.30–1.82) 1.19 (1.08–1.32) 1.31 (1.07–1.59)
0.008
1.22 (0.99–1.50)
0.062
Values are n (%), unless otherwise indicated. All outcomes have been adjusted for randomized treatment and region at baseline. Adjusted model has been adjusted for age,
heart rate, systolic blood pressure, NT-proBNP, BMI, NYHA functional class, LVEF, and eGFR. All outcomes were tested for competing risks of all-cause and noncardiovascular
(non-CV) death. Sudden death was tested for competing risk of all nonsudden deaths and pump failure death for all non–pump failure deaths. Non-CV death was tested for
competing risk of CV death. *Additional adjusted for previous heart failure hospitalization.
Abbreviations as in Table 2.
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FIGURE 2 Clinical Outcomes in Men and Women With Heart Failure With Reduced Ejection Fraction
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Cumulative event curves for (A) primary composite outcome, (B) hospitalization for heart failure (HF), (C) cardiovascular (CV) death, (D) all-cause
death (Kaplan-Meier), (E) sudden death, (F) pump failure death, (G) fatal or nonfatal myocardial infarction (MI), and (H) fatal or nonfatal stroke.
The risk table below the graphs shows the numbers at risk of the event of interest. Women were at reduced risk for all outcomes except stroke
when compared with men. All p values were unadjusted (Fine and Gray).
Dewan et al. J A C C V O L . 7 3 , N O . 1 , 2 0 1 9
Sex Differences in HFrEF J A N U A R Y 8 / 1 5 , 2 0 1 9 : 2 9 – 4 0
36
TABLE 4 Analysis of Repeat Hospitalizations in Men and Women With HFrEF (Negative Binomial Model)
Total Events Events per 100 Person-Years (95% CI) Women vs. Men
Women
(n ¼ 3,357)
Men
(n ¼ 12,058)
Women
(n ¼ 3,357)
Men
(n ¼ 12,058)
Unadjusted IRR
(95% CI) p Value
Adjusted IRR
(95% CI) p Value
HF hospitalization 750 3,569 8.48 (7.89–9.11) 11.40 (11.04–11.79) 0.70 (0.62–0.80)
<0.001
0.69 (0.61–0.79)
<0.001
CV hospitalization 1,719 8,017 19.44 (18.54–20.38) 25.62 (25.07–26.19) 0.74 (0.68–0.81)
<0.001
0.73 (0.67–0.79)
<0.001
Non-CV hospitalization 1,287 5,624 14.55 (13.78–15.37) 17.98 (17.51–18.45) 0.87 (0.80–0.95)
0.001
0.82 (0.75–0.89)
<0.001
All-cause hospitalization 3,006 13,641 33.99 (32.79–35.22) 43.60 (42.87–44.34) 0.79 (0.74–0.84)
<0.001
0.75 (0.70–0.81)
<0.001
Values are n, unless otherwise indicated. Incident rate ratios (IRRs) adjusted for age, previous HF hospitalization, heart rate, systolic blood pressure, NT-proBNP, BMI, NYHA
functional class, LVEF, and eGFR.
Abbreviations as in Table 2 and 3.
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37which appeared relatively underused given the
finding of more congestion in women (7). This
underuse of diuretics, overuse of digoxin, and un-
derutilization of disease-management programs and
exercise prescription in women brings to focus
potentially important questions about the role of
patient sex in doctor–patient communication, pre-
scribing and medical practice more generally (22–26).
Do doctors fail to appreciate the impact of HF in
women compared with men or are women less able
to communicate the severity of the impact of their
illness? We are not aware of prior report of lower
enrollment of women in disease management and
exercise programs but similar underutilization of
cardiac rehabilitation has been reported and the
explanation is likely multifactorial, and includes the
older age of women, comorbidity, and socioeconomic
factors (27). Women may also be more likely to
withdraw from such programs even though trials such
as the HF-ACTION (Heart Failure: A Controlled Trial
Investigating Outcomes of Exercise Training) trial
have shown potentially greater benefit from rehabil-
itation and exercise in women compared with men
(28,29).
In contrast to drugs for HF, device use, especially
implantable cardioverter-defibrillator use, was much
less in women than in men. Further analysis accord-
ing to etiology, NYHA functional class, LVEF, rhythm,
and QRS duration or morphology did not account for
disparity in device use (data not shown). The lower
use of cardiac resynchronization therapy in women is
especially notable, as that this intervention may be
even more effective in women than men and given
that left bundle branch block is more common in
women (as confirmed in the present study), often
with a narrower QRS duration than in men (30).
Anticoagulant use was significantly less common
in women with a history of AF (and in those with AF
on their baseline electrocardiogram), reflectingregistry and “real-world” data showing underuse of
these drugs in women (31). Differences in other
pharmacological therapies appeared to reflect differ-
ences in comorbidities (e.g., the greater use of statins
and aspirin in men likely reflected the higher preva-
lence of CAD in men).
OUTCOMES. As has been shown previously, women
had better outcomes than men (2,3,7). However, we
did analyses additional to those carried out in previous
clinical trial datasets. Because the ATMOSPHERE and
PARADIGM-HF trials were more contemporary than
prior studies, we had a measurement of NT-proBNP
and were able to adjust for this most powerful of all
prognostic variables in HF. Given the lower mortality
rate in women than men, we also analyzed hospitali-
zation for HF, taking account of the competing risk of
death (and examined the total burden of HF hospital-
izations by examining repeat events).
Even after adjusting for NT-proBNP, and other
prognostic variables, women remained less likely to
die than men. Indeed, the differential increased
somewhat so that the adjusted risk of death from any
cause was 32% lower in women, greater than that
identified in the largest prior sex-based analysis in HF
from the CHARM (Candesartan in Heart Failure:
Assessment of Reduction in Mortality and morbidity)
trial (7). We also looked at the 2 major modes of CV
death in HFrEF (i.e., sudden death and death from
pump failure or progressive HF). Both were less
common in women (and the lower risk was propor-
tionally similar for each, in women compared with
men). The explanation for this is unknown, although
1 possibility is the difference that has been described
in cardiac remodeling between men and women,
possibly aggravated by more unfavorable remodeling
in response to ischemic injury in men (with a higher
prevalence of CAD in men) (32,33).
In contrast to death, the lower risk of a first HF
hospitalization was less marked: women were 20%
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38less likely to be hospitalized for HF than men were.
This more modest relative risk may be because we
accounted for the substantial competing risk of death.
Interestingly, the lower risk of HF hospitalization inwomen was apparent for second and subsequent (and
not just first) admissions, and the sex difference was
larger when repeat admissions were examined.
Moreover, the risk of hospitalization for any CV
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Women with
HFrEF are generally older and have a greater symptom burden
and more impaired quality of life, but less frequent hospitaliza-
tion and longer survival than men with this condition.
TRANSLATIONAL OUTLOOK: Future studies should address
these differences in evaluating therapeutic strategies for women
with HFrEF. The lower prevalence of HFrEF in women is 1 factor
limiting representation of women in clinical trials, while lower
event rates in women than men compounds the challenge of
assessing the relative risks and benefits of these interventions.
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39reason and for any reason at all was lower in women
(although the largest sex-difference was seen for HF
and the smallest for all-cause hospitalization). The
absolute differences were substantial when repeat
events were considered: 3, 6, and 10 fewer admissions
per 100 person-years of follow-up in women,
compared with men, for HF, any CV reason, and all
causes, respectively.
Collectively, these differences in symptoms,
HRQL, mortality, and hospitalization highlight some
interesting sex-related paradoxes. Intuitively, worse
symptoms or HRQL might have been expected to be
associated with higher (rather than lower) rates of
hospitalization. Similarly, better survival might have
led to a higher lifetime burden of hospital admissions
(especially if longevity was associated with greater
symptoms and worse HRQL). In both cases the
converse was observed, with women living longer
than men but experiencing poorer HRQL during their
additional years of life. The explanation for the
disconnect between symptoms or HRQL and hospital
admission rates is uncertain. Is it just about women’s
perception of the impact of their disease or are there
sex-related confounders not measured in this study
(e.g., differences in access to health care, less care-
giver support or living alone, socioeconomic and
educational factors, and less proactive seeking of
help)?
More expected from the difference in background
CAD, the risk of MI was lower in women than in men.
Conversely, the risk of stroke was greater and may, in
part, be explained by the lower rate of anticoagulation
in women, as mentioned previously, as well as the
higher prevalence of hypertension in women.
There are 2 other recent reports about sex-related
differences in HF trials. The STICH (Surgical Treat-
ment for Ischemic Heart Failure) trial enrolled 148
women between 2004 and 2007 and the EchoCRT
(Echocardiography Guided Cardiac Resynchroniza-
tion Therapy) trial enrolled 224 women between 2008
and 2013 (34,35). Apart from the small number of
women in both these trials, it is difficult to draw any
general conclusions because patients were also highly
selected for specific interventions and the EchoCRT
trial was stopped early for harm, with only 64 primary
events among women.
STUDY STRENGTHS AND LIMITATIONS. The patients
enrolled were selected and are potentially better
treated than are those in the “real world.” We focused
on HFrEF, whereas many women with HF have pre-
served LVEF. We did not have serial assessments ofleft ventricular structure and function. Our study has
strengths as well. It is the only large, contemporary,
clinical trial dataset with many women. In trials, pa-
tients are well characterized, and outcomes are care-
fully collected and adjudicated. Because of the
increasing globalization of trials, we were able to
report the most geographically representative anal-
ysis of women with HFrEF to date.
CONCLUSIONS
While women with HFrEF have fewer comorbidities,
better survival, and lower rates of hospitalization,
they have more symptoms and worse HRQL than men
do. They also report much more anxiety or depres-
sion. Women appeared relatively undertreated with
diuretics given their greater evidence of congestion,
and devices were underutilized more in women than
in men. Women were less often referred to a disease
management program or prescribed an exercise
regimen. Although women with HFrEF live longer
than men do, their additional years of life are of
poorer quality, with greater self-reported psycholog-
ical and physical disability. This different sex-related
experience of HFrEF is unexplained and it is uncer-
tain whether physicians recognize it. Women
continue to receive suboptimal treatment, compared
with men.
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